Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may

Editorial

Charles D Blanke. J Clin Oncol. 2009.

. 2009 Feb 10;27(5):655-8.

doi: 10.1200/JCO.2008.21.2522. Epub 2008 Dec 29.

Erratum in

No abstract available

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Bokemeyer C, et al. J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29. J Clin Oncol. 2009. PMID: 19114683 Clinical Trial.
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. Hecht JR, et al. J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29. J Clin Oncol. 2009. PMID: 19114685 Clinical Trial.